men1309
mAbexperimentalADC
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 28, 2017 (NCT03403725)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Lymphocyte antigen 75INHIBITOR
LY75 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- Ravtansine
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03403725 | Phase 1 | Aug 28, 2017 | Menarini Group, Universidad Autonoma de Barcelona |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Menarini Group | For profit | 1 | 1 | 1 | 2017 |
| Universidad Autonoma de Barcelona | Academic/Hospital | 1 | 0 | 1 | 2017 |
2 organizations
Page 1 / 1